O'Brien Sarah 4
4 · Provention Bio, Inc. · Filed Jan 11, 2023
Insider Transaction Report
Form 4
O'Brien Sarah
Chief People Officer
Transactions
- Award
Stock Option (right to buy)
2023-01-10+8,000→ 108,000 totalExercise: $5.35From: 2023-01-10Exp: 2032-09-15→ Common Stock, par value $0.0001 (8,000 underlying) - Award
Stock Option (right to buy)
2023-01-10+100,000→ 100,000 totalExercise: $8.93Exp: 2033-01-10→ Common Stock, par value $0.0001 (100,000 underlying)
Footnotes (4)
- [F1]As previously reported on a Form 4 filed on September 19, 2022, on September 15, 2022, the Reporting Person was granted a stock option for 200,000 shares of Common Stock, 100,000 of which option shares vest in four equal annual installments commencing on September 15, 2023 and 100,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 8,000 of the 100,000 performance options shares on January 10, 2023 upon the satisfaction of certain performance milestones.
- [F2]The stock options were granted pursuant to the Issuer's 2020 Inducement Plan, as amended.
- [F3]The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027).
- [F4]The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.